Clementia Pharmaceuticals (Clementia Pharmaceuticals) Accounts Receivable : $0.00 Mil (As of Dec. 2018)

View and export this data going back to 2017. Start your Free Trial

What is Clementia Pharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Clementia Pharmaceuticals's accounts receivables for the quarter that ended in Dec. 2018 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Clementia Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2018 was $4.16.

Clementia Pharmaceuticals Accounts Receivable Historical Data

The historical data trend for Clementia Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clementia Pharmaceuticals Accounts Receivable Chart

Clementia Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Accounts Receivable

Clementia Pharmaceuticals Quarterly Data
	Dec14	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
Accounts Receivable	Get a 7-Day Free Trial									-	-	-	-	-

Clementia Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Clementia Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Clementia Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2018 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Clementia Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Clementia Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2018 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(169.973	+	0.75 * 0	+	0.5 * 0	-	12.412
-	0	-	0)	/	37.8641
=	4.16

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Clementia Pharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Clementia Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Clementia Pharmaceuticals (Clementia Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clementia Pharmaceuticals Inc (NAS:CMTA) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

4150 St Catherine Street West, Suite 550, Montreal, QC, CAN, H3Z 2Y5

Website

http://www.clementiapharma.com

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). It believes that if approved in FOP or MO, palovarotene could become the standard of care in either or both of these indications.